title: Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.
abstract: Lung cancer is among the most prevalent and deadly cancers. Although the development of targeted drugs, erlotinib and crizotinib, has improved lung cancer management, survival rates of lung cancer patients have not shown significant improvement over the past decade. Better therapeutic options are required to treat lung cancer patients. Immunotherapy is a maturing and rapidly growing field, which has recently contributed many novel strategies for addressing cancer treatment. Here, we discuss the current state of cancer vaccines, immune checkpoint blockers, and adoptive cellular therapies, as novel clinical treatment strategies for non-small cell lung cancer. The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism.
authors.forename: Shawn J
authors.initials: SJ
authors.lastname: Rice
authors.forename: Bruce
authors.initials: B
authors.lastname: Miller
authors.forename: Matthias
authors.initials: M
authors.lastname: Wagman
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Jamorabo
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.affiliation: Penn State Hershey Cancer Institute, Penn State College of Medicine, 500 University Dr, Hershey, PA 17033, USA. cbelani@hmc.psu.edu.
authors.forename: Chandra P
authors.initials: CP
authors.lastname: Belani
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007167:Immunotherapy / Q000639:trends*; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D007155:Immunologic Factors